# Jeremy Hamm

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeremy-hamm/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,105 |
| Field | Prostate Cancer Diagnosis and Treatment |
| h-index | 19 |
| i10-index | 36 |
| OpenAlex ID | https://openalex.org/A5083892351 |
| ORCID iD | 0000-0002-0700-8641 |
| Works | 87 |

## Researcher papers

- [Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer](https://scholariq.org/papers/androgen-suppression-combined-with-elective-nodal-and-dose-escalated-radiation/)
- [ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer](https://scholariq.org/papers/ascende-rt-an-analysis-of-treatment-related-morbidity-for-a-randomized-trial/)
- [ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer](https://scholariq.org/papers/ascende-rt-an-analysis-of-health-related-quality-of-life-for-a-randomized-trial/)
- [ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.](https://scholariq.org/papers/ascende-rt-a-multicenter-randomized-trial-of-dose-escalated-external-beam/)
- [An Updated Analysis of the Survival Endpoints of ASCENDE-RT](https://scholariq.org/papers/an-updated-analysis-of-the-survival-endpoints-of-ascende-rt/)
- [Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?](https://scholariq.org/papers/incomplete-testosterone-suppression-with-luteinizing-hormone-releasing-hormone/)
- [Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival](https://scholariq.org/papers/prostate-specific-antigen-at-4-to-5-years-after-low-dose-rate-prostate/)
- [Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma](https://scholariq.org/papers/secondary-breast-cancer-risk-by-radiation-volume-in-women-with-hodgkin-lymphoma/)
- [Surgeon Volume, Patient Age, and Tumor-Related Factors Influence the Need for Re-Excision After Breast-Conserving Surgery](https://scholariq.org/papers/surgeon-volume-patient-age-and-tumor-related-factors-influence-the-need-for-re/)
- [Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases](https://scholariq.org/papers/institutional-analysis-of-stereotactic-body-radiotherapy-sbrt-for/)
- [Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients](https://scholariq.org/papers/breast-conserving-therapy-is-associated-with-improved-survival-without-an/)

## Researcher topics

- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.